Literature DB >> 21480820

Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know.

Drew R Jones1, Grover P Miller.   

Abstract

INTRODUCTION: Coumadin (R/S-warfarin) is the most widely prescribed oral anticoagulant in the world; nevertheless, its clinical use is complicated by unpredictability in dose requirements to achieve and maintain optimal anticoagulation. Variations in warfarin metabolism among patients contribute to unpredictability in therapeutic responses. Studying the clinical relevance of warfarin metabolism poses a significant analytical challenge. Warfarin is given to patients as an equal mixture of R and S enantiomers. Both drugs undergo extensive metabolism through different pathways to generate > 20 structurally similar isomeric metabolites. AREAS COVERED: The article discusses how analytical methods have evolved to effectively resolve and quantify individual metabolites. The authors also discuss how the application of these methods has identified clinically relevant metabolic pathways for warfarin and fostered the investigation of clinical biomarkers for patient responses to therapy. The article additionally presents the power of these methods and how aspects of warfarin metabolism have led to the use of warfarin as a phenotyping probe for multiple drug metabolizing enzymes. EXPERT OPINION: Progress in these areas has been hampered by shortcomings in analytical methods and a narrow focus on one metabolic pathway. Recent advances in liquid chromatographic-mass spectral methods can rapidly analyze most warfarin metabolites. It is now possible to effectively assess alternate metabolic pathways and expand biomarker analyses for clinical and phenotyping applications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21480820     DOI: 10.1517/17425255.2011.576247

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  7 in total

Review 1.  The emerging threat of superwarfarins: history, detection, mechanisms, and countermeasures.

Authors:  Douglas L Feinstein; Belinda S Akpa; Manuela A Ayee; Anne I Boullerne; David Braun; Sergey V Brodsky; David Gidalevitz; Zane Hauck; Sergey Kalinin; Kathy Kowal; Ivan Kuzmenko; Kinga Lis; Natalia Marangoni; Michael W Martynowycz; Israel Rubinstein; Richard van Breemen; Kyle Ware; Guy Weinberg
Journal:  Ann N Y Acad Sci       Date:  2016-05-31       Impact factor: 5.691

2.  Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites.

Authors:  C Preston Pugh; Dakota L Pouncey; Jessica H Hartman; Robert Nshimiyimana; Linda P Desrochers; Thomas E Goodwin; Gunnar Boysen; Grover P Miller
Journal:  Arch Biochem Biophys       Date:  2014-10-19       Impact factor: 4.013

3.  Stereospecific Metabolism of R- and S-Warfarin by Human Hepatic Cytosolic Reductases.

Authors:  Dustyn A Barnette; Bryce P Johnson; Dakota L Pouncey; Robert Nshimiyimana; Linda P Desrochers; Thomas E Goodwin; Grover P Miller
Journal:  Drug Metab Dispos       Date:  2017-06-23       Impact factor: 3.922

4.  Simultaneous Characterization and Determination of Warfarin and Its Hydroxylation Metabolites in Rat Plasma by Chiral Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Shasha Jin; Zhihong Li; Qing Yang; Boyu Fang; Xiaoqiang Xiang; Chao Peng; Weimin Cai
Journal:  Pharmaceutics       Date:  2022-05-27       Impact factor: 6.525

5.  Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins.

Authors:  So-Young Kim; Ji-Yeon Kang; Jessica H Hartman; Sun-Ha Park; Drew R Jones; Chul-Ho Yun; Gunnar Boysen; Grover P Miller
Journal:  Drug Metab Lett       Date:  2012-09-01

6.  Discovery of Novel Reductive Elimination Pathway for 10-Hydroxywarfarin.

Authors:  Dakota L Pouncey; Dustyn A Barnette; Riley W Sinnott; Sarah J Phillips; Noah R Flynn; Howard P Hendrickson; S Joshua Swamidass; Grover P Miller
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

7.  The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight.

Authors:  Pietro Scicchitano; Marco Tucci; Maria Consiglia Bellino; Francesca Cortese; Annagrazia Cecere; Micaela De Palo; Francesco Massari; Pasquale Caldarola; Francesco Silvestris; Marco Matteo Ciccone
Journal:  Cardiovasc Drugs Ther       Date:  2021-06       Impact factor: 3.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.